Galectin Therapeutics (GALT) Shares Outstanding (Weighted Average) (2010 - 2026)

Galectin Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $65.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 1602.64% year-over-year to $65.8 million; the trailing twelve-month figure through Mar 2026 stood at $65.8 million (up 1602.64% YoY), and the FY2025 full-year result was $4.2 million, down 93.3% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $65.8 million, up from $4.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $65.8 million in Q1 2026, with the low at $3.9 million in Q1 2025.
• Average Shares Outstanding (Weighted Average) over 5 years is $54.5 million, with a median of $59.7 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) slumped 93.77% in 2025 and jumped 1602.64% in 2026.
• Tracing GALT's Shares Outstanding (Weighted Average) over 5 years: stood at $59.4 million in 2022, then gained by 1.29% to $60.2 million in 2023, then advanced by 3.57% to $62.3 million in 2024, then sank by 93.3% to $4.2 million in 2025, then surged by 1476.7% to $65.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $65.8 million (Q1 2026), $4.2 million (Q4 2025), and $63.6 million (Q3 2025), per Business Quant data.

Peer Comparison